Keeps Biopharma: Major Management Disclosure: Approval of Phase 2 IND for Idetrexed (CT900)-based anticancer therapy
AI reading
★★★ Bullish · Material event
Approval of Phase 2 IND for Idetrexed anticancer therapy
Key figures: Phase 2 clinical trial
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
For information only. Not investment advice.